ライフサイエンスコーパス: prostacyclin synthase

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 zymes, endothelial nitric oxide synthase and prostacyclin synthase.

2 uced insulin-resistant mice--inactivation of prostacyclin synthase and eNOS was prevented by inhibiti

3 tivated 2 important antiatherogenic enzymes, prostacyclin synthase and eNOS.

4 d ELPCs (expressing cyclooxygenase isoform 1-prostacyclin synthase and nuRFP) were tested in rats wit

5 y, we observed that COX-2 deletion decreased prostacyclin synthase and production and peroxisome prol

6 ric oxide synthase-3) nitric oxide synthase, prostacyclin synthase, and constitutive cyclooxygenase (

7 Nitric oxide synthase, prostacyclin synthase, and tissue inhibitors of metallop

8 NA and protein levels of cPLA(2), COX-2, and prostacyclin synthase, as well as the promoter and enzym

9 Similarly, bovine prostacyclin synthase catalyzed the isomerization of the

10 und II in analogy with plant AOS (CYP74) and prostacyclin synthase (CYP8A1).

11 tacyclin) by lung-specific overexpression of prostacyclin synthase decreases lung tumor incidence and

12 HIF-responsive genes (VEGF-A, PPARgamma, and prostacyclin synthase) due to an insufficient increase i

13 Cyclooxygenase isoform 1-prostacyclin synthase-expressing ELPCs reversed MCT-indu

14 ressing a human cyclooxygenase isoform 1 and prostacyclin synthase fusion protein that produces prost

15 activation suppressed tyrosine nitration of prostacyclin synthase in diabetes.

16 ypothesized that pulmonary overexpression of prostacyclin synthase may prevent the development of mur

17 addition of AICAR reduced both O(2).(-) and prostacyclin synthase nitration caused by high glucose,

18 lting in the inhibition of both O(2).(-) and prostacyclin synthase nitration in diabetes.

19 P-2 expression and reduced both O(2).(-) and prostacyclin synthase nitration in diabetic wild-type mi

20 CP-2 significantly ablated both O(2).(-) and prostacyclin synthase nitration triggered by high glucos

21 ) increased superoxide anions (O(2).(-)) and prostacyclin synthase nitration.

22 Transgenic FVB/N mice with lung-specific prostacyclin synthase overexpression were exposed to mai

23 Transgenic mice with selective pulmonary prostacyclin synthase overexpression were exposed to two

24 We hypothesized that pulmonary prostacyclin synthase overexpression would prevent lung

25 nes (angiotensin-converting enzyme [ACE] and prostacyclin synthase [PGI2S]) were measured in samples

26 ived from adenoviral cyclo-oxygenase (COX)-1/prostacyclin synthase (PGIS) (Adv-COPI) gene transfer in

27 The eicosanoid pathway enzymes prostacyclin synthase (PGIS) and inducible prostaglandin

28 s to determine whether tyrosine nitration of prostacyclin synthase (PGIS) contributes to retinal cell

29 Prostacyclin synthase (PGIS) is a membrane-bound class I

30 Prostacyclin synthase (PGIS) is the final committed enzy

31 Prostacyclin synthase (PGIS) is tyrosine nitrated in dis

32 The most significant interaction was at prostacyclin synthase (PGIS) rs5602 (OR = 0.34, 95% CI 0

33 Prostacyclin synthase (PGIS), a cytochrome P450 enzyme,

34 sis via tyrosine nitration and inhibition of prostacyclin synthase (PGIS), an enzyme with antithrombo

35 rdinate up-regulation of cPLA(2), COX-2, and prostacyclin synthase (PGIS).

36 ransfected with the cyclooxygenase isoform 1-prostacyclin synthase plasmid and labeled with lentiviru

37 We demonstrated differences of prostacyclin synthase promoter activities dependent on t

38 Prostacyclin synthase promoter haplotypes' transcription

39 g prostacyclin analogs, we hypothesized that prostacyclin synthase promoter sequence variants associa

40 Prostacyclin synthase promoter sequence variants exhibit

41 We identified a comprehensive set of prostacyclin synthase promoter variants and tested their

42 in reaction approaches were used to genotype prostacyclin synthase promoter variants in more than 300

43 To determine the distribution of prostacyclin synthase promoter variants in PAH, unaffect

44 iscovered a significant bias for more active prostacyclin synthase promoter variants in unaffected ca

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。